A randomized double-blind placebo controlled multi-center study to

Recruiting

1 years - 99 years

All

1 Location

Brief description of study

A multi-center study evaluating the effects of ranolazine in subjects with class II/III/IV pulmonary hypertension on stable background therapy and persistent RV dysfunction. Study involves an observational arm and a 26-week treatment arm. At baseline (wk 0), interim (wk 13) and the conclusion of treatment period (wk 26) subjects will be assessed for functional class, 6- MWD, and QOL based on SF-36 tool. Subjects will be assessed with echo and peripheral blood will be obtained for metabolic profiling at baseline and the conclusion of the treatment period. Subjects will have baseline cardiac MRI done per standard of care or will have it done as part of the companion research imaging protocol. Subjects must enroll in companion imaging protocol to qualify for the treatment protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Hypertension, pulmonary, pulmonary, hypertension
Age: 1 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 817785

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).